Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-03-01
2011-03-01
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S281100
Reexamination Certificate
active
07897156
ABSTRACT:
The invention concerns the use of a virus to increase the number of dendritic cells or their precursor cells in an immunocompromised animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara which is capable of infecting the cells of a neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human.
REFERENCES:
patent: 3914408 (1975-10-01), Mebus
patent: 4191745 (1980-03-01), Mayr et al.
patent: 5338683 (1994-08-01), Paoletti
patent: 5403582 (1995-04-01), Nazerian et al.
patent: 5405772 (1995-04-01), Ponting
patent: 5753489 (1998-05-01), Kistner et al.
patent: 5756341 (1998-05-01), Kistner et al.
patent: 5770212 (1998-06-01), Falkner et al.
patent: 5843456 (1998-12-01), Paoletti et al.
patent: 6190655 (2001-02-01), Lyman et al.
patent: 6204250 (2001-03-01), Bot et al.
patent: 6605465 (2003-08-01), Paoletti
patent: 6685950 (2004-02-01), Weber et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6805870 (2004-10-01), Mayr
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 7097842 (2006-08-01), Suter et al.
patent: 7189536 (2007-03-01), Chaplin et al.
patent: 7335364 (2008-02-01), Chaplin et al.
patent: 7338662 (2008-03-01), Howley et al.
patent: 7384644 (2008-06-01), Chaplin et al.
patent: 7445924 (2008-11-01), Chaplin et al.
patent: 7618980 (2009-11-01), Fevig et al.
patent: 7628980 (2009-12-01), Suter et al.
patent: 2003/0215466 (2003-11-01), Chaplin et al.
patent: 2004/0091995 (2004-05-01), Schlom et al.
patent: 2005/0214323 (2005-09-01), Chaplin et al.
patent: 2006/0127984 (2006-06-01), Ackermann et al.
patent: 2006/0280758 (2006-12-01), Chaplin et al.
patent: 2008/0089907 (2008-04-01), Chaplin et al.
patent: 2009/0169579 (2009-07-01), Chaplin et al.
patent: 2010/0119545 (2010-05-01), Chaplin et al.
patent: 1335987 (2005-12-01), None
patent: 2370573 (2002-07-01), None
patent: 90/12882 (1990-11-01), None
patent: 95/22978 (1995-08-01), None
patent: 97/02355 (1997-01-01), None
patent: 97/31119 (1997-08-01), None
patent: 98/13500 (1998-04-01), None
patent: 98/17283 (1998-04-01), None
patent: 98/56919 (1998-12-01), None
patent: 99/07869 (1999-02-01), None
patent: 00/29428 (2000-05-01), None
patent: 01/68820 (2001-09-01), None
patent: 01/95919 (2001-12-01), None
patent: 02/42480 (2002-05-01), None
patent: WO 2005/046614 (2005-05-01), None
Mayr et al (Developments in Biological Standardization 41:255-234, 1978).
Vollstedt et a., Flt3 Ligand-treated Neonatal Mice Have Increased Innate Immuity Against Intracellular Pathogens and Efficiently Control Virus Infections, J. Exp. Med. 197:575-584 (2003).
Franchini et al., Dendritic Cells from Mice Neonatally Vaccinated with Modificed Vaccinia Virus Ankara Transfer Resistance against Herpes Simplex Virus Type I to Naive One-Week-Old Mice1, J. Immunology 172: 6304-6312 (2004).
Sutter et al., Nonreplicating vaccinia vector efficiently expresses recombinant genes. P.N.A.S. 89:10847-10851, 1992.
Blanchard et al., Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen Virology 79:1159-1167, 1998.
Schiver et al., Replication-incomptent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335, 2002.
Drexler et al., Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanmaasociated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo. Cancer Research 59:4955-5963, 1993.
Oxford Biomedica PLC et al., Defendants' Answer to Plaintiff'S First Amended Complaint and Counterclaims, Case No. 08cv1156-MMA (RBB), Jun. 1, 2009.
Bavarian Nordic A/S, Plaintiffs Answers to Defendants' Counterclaims, Case No. 08cv1156- MMA (RBB), Jun. 22, 2009.
Bavarian Nordic A/S, Plaintiffs Motion for Partial Summary Judgement on Inequitable Conduct, Case No. 08cv1156-MMA (RBB), Jan. 25, 2010.
Declaration of Theodore J. Folkman, Case No. 08cv1156-MMA (RBB), Jan. 25, 2010.
Suter et al., Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain, Vaccine 27:7442-7450 (2009).
Opposition Division, EPO, Opposition to EP Patent No. 1420822, EPA Form 2906, Oct. 8, 2009.
Emergent Product Development Germany GMBH, Opposition to EP Patent No. 1420822, Reply Letter, Sep. 23, 2009.
Bavarian Nordic, Opposition to EP Patent No. 1420822, Patentee Response to Oppositions, Mar. 27, 2009.
Sanofi Pasteur, Opposition to EP Patent No. 1420822, Notice of Opposition, Apr. 11, 2008.
Emergent Product Development Germany GMBH, Opposition to EP Patent No. 1420822, Notice of Opposition, Apr. 8, 2008.
Dr. Elfriede Dworak of the Commertcial Court of Vienna, Austria, Decision on Initial Matter, without prejudice, in Case 19Cg 25/06g, May 31, 2007.
Mayr & Mayr, Pesq. Vet. Bras. 19:91-98 (1999).
Mayr et al., Infection 3:6-14 (1975).
Mayr et al., J. Vet Med. B. 3681-99 (1989).
Mayr et al., Drug Res. 37:988-989 (1987).
Mayr et al., J. Vet Med. B. 33:321-339 (1986).
Dr. Paul Chaplin, ITC Testimony, ITC Investigation No. 337-TA-550, 447-706, May 10, 2006.
Mayr, Swiss Vet.11:13-17 (1999).
Paul Luckern, ALJ, Order No. 5, ITC Investigation No. 337-TA-550, Jun. 29, 2007.
Bavarian Nordic, 1999 Annual Report, Mar. 14, 2000.
Bavarian Nordic, 2000 Annual Report, Mar. 6, 2001.
Oxford Biomedica (UK) LTD, Opposition to EP Patent No. 1335987, Additional Submissions, Dec. 7, 2009.
Bavarian Nordic, Opposition to EP Patent No. 1335987, Reply to Submissions, Jun. 18, 2008.
Oxford Biomedica (UK) LTD, Opposition to EP Patent No. 1335987, Reply to Patentee's Response, Jan. 28, 2008.
Emergent Product Development Germany GMBH, Opposition to EP Patent No. 1335987, Submission to Patentee's Observations, Mar. 12, 2008.
Bavarian Nordic, Opposition to EP Patent No. 1335987, Response to Oppositions, Aug. 1, 2007.
Emergent Product Development Germany GMBH, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 28, 2006.
VIRBAC SA, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 28, 2006.
Innogenetics NV, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 27, 2006.
Oxford Biomedica (UK) LTD, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 26, 2006.
Baxter Ag, Opposition to EP Patent No. 1335987, Notice of Opposition, May 15, 2006.
Sanofi Pasteur Inc, Opposition to EP Patent No. 1335987, Notice of Opposition, Sep. 26, 2006.
Acambis PLC, Opposition to EP Patent No. 1335987, Notice of Opposition, May 15, 2006.
Drexler et al., Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host ofr virus propagation, but not in various human transformed and primary cells, Journal of General Virology (1998), 79, 347-352.
Drexler, et al., J. Gen. Virol. (1998) 79:347-352.
International Preliminary Examination Report, dated Jan. 11, 2006, four (4) pages.
Tartaglia, et al. “NYVAC: a highly attenuated strain of vaccinia virus”—Virology 1992, vol. 188, pp. 217-232.
Kovarik, et al. “Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC (K1L) viral vector” Virology Jun. 20, 2001, vol. 285, pp. 12-20.
Kazanji. et al. “Immunogenicity and protective efficacy of recombinant human T-cell leukaemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus)” Journal of Virology, Jul. 2001, vol. 75(13), pp. 5939-5948.
U.S. International Trade Commission, Inv. No. 337-Ta-550, Order No. 10: Denying Respondent's Motion to Terminate and Entry of Consent Order, Nov. 30, 2005, pp. 1-8.
Inv. No. 337-TA-550, Complainant Bavarian Nordic's Motion for Summary Determination of Infringement of the '893 Patent, Mar. 20, 2005, pp. 1-15.
U.S. International Trade Commission, Inv. No. 337-TA-550, Co
Ackermann Mathias
Chaplin Paul
Franchini Marco
Hefti Hans Peter
Hefti, legal representative Ruth
Bavarian Nordic A/S
Law Office of Salvatore Arrigo
Mosher Mary E
LandOfFree
Modified vaccinia virus ankara for the vaccination of neonates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vaccinia virus ankara for the vaccination of neonates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vaccinia virus ankara for the vaccination of neonates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2753742